The Effect of GCSF in the Treatment of ALS Patients

The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013

The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.

Inclusion Criteria:

• age between 18 and 85
• definite or probable ALS according to revised El Escorial criteria
• maximum 2 years from initiation of symptoms to study entry
• mild to moderate disability according to revised ALS functional rating scale (ALSFRS-r)

Exclusion Criteria:

• familial ALS
• pregnancy or lactation
• myeloproliferative or hematologic disorders
• active immunological disease
• liver or renal or heart disease
• HIV positive
• significant cognitive disorder
• hypersensitivity to GCSF